Alnylam Pharmaceuticals Inc
(NAS:ALNY)
$
266.255
-2.695 (-1%)
Market Cap: 34.34 Bil
Enterprise Value: 33.29 Bil
PE Ratio: 0
PB Ratio: 1,065.02
GF Score: 78/100 
Alnylam Pharmaceuticals Inc at Stifel CNS Days (Virtual) Transcript
Mar 28, 2022 / 06:00PM GMT
Release Date Price:
$161.65
(-1.32%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Great. Thanks very much. It's my pleasure to be moderating this panel with Kevin Fitzgerald, Alnylam's Chief Scientific Officer. And on this panel, we're going to specifically talk about Alnylam's efforts in neuroscience as you guys are expecting some proof of principle, proof of concept data by the end of this year.
Questions & Answers
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
So maybe, Kevin, to kind of kick it off, right? I think most folks know about the history of GalNAc in the liver, what did you need to achieve to be able to safely deliver RNAi therapeutics that can penetrate and engage the target in different areas of the brand?
Kevin Joseph Fitzgerald
Alnylam Pharmaceuticals, Inc. - Senior VP, Head of Research & Chief Scientific Officer
Yes. So thank you for
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers